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Abstract Heme oxygenase (HO)-1 catalyzes the rate-limiting
step in heme degradation releasing iron, carbon monoxide, and
biliverdin. Induction of HO-1 occurs as an adaptive and
protective response to oxidative stress. Ischemia and reperfusion
(IR) injury seems to be mainly caused by the oxidative stress. In
this study, we have examined whether prior induction of HO-1
with buthionine sulfoximine (BSO), a glutathione (GSH)
depletor, affects the subsequent renal IR injury. BSO (2 mmol/
kg body weight) was administered intraperitoneally into rats, the
levels of HO-1 protein increased within 4 h after the injection.
When BSO was administered into rats at 5 h prior to the renal 45
min of ischemia, the renal IR injury was assessed by determining
the levels of blood urea nitrogen and serum creatinine, markers
for renal injury, after 24 h of reperfusion. The renal injury was
significantly improved as compared to the rats treated with IR
alone. Administration of zinc-protoporphyrin IX, an inhibitor of
HO activity, reduced the efficacy of BSO pretreatment on the
renal IR injury. Our findings suggest that the prior induction of
HO-1 ameliorates the subsequent renal IR injury. ß 2002 Fed-
eration of European Miochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Heme oxygenase (HO) is the rate-limiting enzyme that cat-
alyzes the conversion of heme into biliverdin, carbon monox-
ide, and free iron [1]. Biliverdin is subsequently reduced by
biliverdin reductase to form bilirubin, which scavenges reac-
tive oxygen species. Two isoforms of HO have been exten-
sively characterized: an inducible enzyme (HO-1) and a con-
stitutive isoform (HO-2) [2]. Recently, a third isoform (HO-3)
has been identi¢ed but its function is still unknown [3]. HO-1
is upregulated following various stimuli, including heme,
heavy metals, cytokines, hormones, endotoxins, and heat
shock, and is considered to be one of the most sensitive in-
dicators of cellular oxidative stress [4,5].
It has been shown that HO-1 is induced in the kidneys in
certain models of acute renal injury: glycerol-induced acute
renal failure [6^8], nephrotoxic serum nephritis [6], and cispla-
tin nephrotoxicity [9]. Induced HO-1 protein was mainly lo-
calized in renal tubules, which were damaged regions, of rat
models of rhabdomyolysis and nephrotoxic serum nephritis
[6,7]. In a rat model of rhabdomyolysis, Nath’s group re-
ported that prior induction of HO-1 by preinfusion of hemo-
globin prevented the renal failure and reduced mortality [6].
Under these conditions, administration of a speci¢c inhibitor
of HO activity worsened the renal damage further [6]. Hence,
the stimulation of HO-1 activity with some non-toxic drug
may represent a novel therapeutic approach in the ameliora-
tion of acute renal injury and other tissue insults.
It has been reported that HO-1 is induced by agents that
are known to interact with or modify cellular glutathione
(GSH) levels [10]. GSH is considered to be an important
cellular antioxidant [11,12]. Therefore, it is tempting to spec-
ulate that the induced HO-1 expression by changing the intra-
cellular redox state may protect the oxidative injury.
In this study, we investigated whether prior induction of
HO-1 by buthionine sulfoximine (BSO), an inhibitor of Q-glu-
tamylcysteine synthetase that is the rate-limiting enzyme in
GSH biosynthesis, ameliorates the renal ischemia and reper-
fusion (IR) injury.
2. Materials and methods
2.1. Induction of acute renal injury
All animal experiments were performed following the institution’s
criteria for the care and use of laboratory animals. Male Wistar rats
(200^250 g) were used. Animals were fed standard rodent chow and
water ad libitum. Surgical operation was performed under intraperi-
toneal sodium pentobarbital (50 mg/kg body weight) anesthesia. For
the renal ischemia, the right kidney was removed 3 weeks before the
ischemia. Left renal ischemia was conducted for 45 min of occlusion
of the renal artery and vein followed by 24 h of reperfusion. Occlusion
was veri¢ed visually by change in the color of the kidneys to a paler
shade and reperfusion by a blush. GSH depletion was induced by
intraperitoneal injection of BSO (2 mmol/kg body weight). Zinc-pro-
toporphyrin IX (ZnPP), an inhibitor of HO activity, was twice in-
jected into rats subcutaneously at 3 and 16 h before the start of
ischemia.
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2.2. Assessment of renal injury
At the end of the experimental protocol, the rats were anesthetized
with ether, the chest and peritoneal cavities were opened carefully,
and blood was drawn from the heart. For the assessment of renal
injury, blood urea nitrogen (BUN) and serum creatinine (SCr) levels
were measured.
2.3. Biochemical analysis
Total GSH (reduced and oxidized forms) contents were measured
with the GSH reductase^5,5P-dithiobis(2-nitrobenzoic acid) (DTNB)
recirculating assay [13]. The tissue (0.2 g) was homogenized in 5 ml of
0.1 M phosphate bu¡er (pH 7.5) at 0‡C and mixed with 2.5 ml of 10%
trichloroacetic acid solution. The mixture was centrifuged at 1500Ug
for 15 min. One ml of supernatant was extracted three times with 2 ml
of cold ether. Each assay contained 0.2 mM reduced NADPH, 0.6
mM DTNB, 0.6 U of GSH reductase and 100 Wl of sample in a ¢nal
volume of 1 ml. The reaction was started by the addition of GSH
reductase. The rate of formation of reduced DTNB was followed at
415 nm.
2.4. Western blot analysis
Tissue extracts from kidneys were prepared as follows. Kidneys
were homogenized in 10 volumes of homogenization bu¡er, which
contained 20 mM Tris^HCl (pH 7.5), 2 mM EDTA, 1 mM dithio-
threitol, 1% Tween 20, 1 mM phenylmethylsulfonyl £uoride, 10 Wg/ml
aprotinin and centrifuged at 8000Ug for 10 min at 4‡C, and the
resulting supernatants were used as tissue extracts. The extracts (100
Wg protein/sample) were subjected to 12.5% sodium dodecyl sulfate^
polyacrylamide gel electrophoresis (SDS^PAGE) [14]. After electro-
phoresis, the fractionated proteins were electrophoretically blotted
onto nitrocellulose ¢lters. The membranes were ¢rst treated with 3%
non-fat dry milk in TBST solution (150 mM NaCl, 50 mM Tris^HCl,
pH 7.4, and 0.05% Tween 20) for 1 h and then incubated with anti-
body against rat HO-1 or HO-2 (diluted 1000-fold, StressGen, Victo-
ria, BC, Canada) in 3% non-fat dry milk in TBST solution for 1 h at
room temperature. The ¢lters were washed three times with TBST
solution for 10 min each to remove any unbound antibodies and
then were incubated for 1 h at room temperature with alkaline phos-
phatase-conjugated goat anti-rabbit IgG (Boehringer Mannheim,
Mannheim, Germany) in 3% non-fat dry milk in TBST solution. After
washing three times with TBST solution for 10 min each and once
with 100 mM Tris^HCl (pH 9.5) solution containing 100 mM NaCl
and 10 mM MgCl2, the immunoreactive bands were visualized using
5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium chlo-
ride as recommended by the supplier.
2.5. Histology
The rats were killed and the isolated kidneys were subjected to
histological analysis. The kidneys were immediately ¢xed with 10%
formalin, and were processed for para⁄n embedding. 4-Wm-thick par-
a⁄n sections were stained with hematoxylin and eosin.
2.6. Statistics
The data were expressed as mean þ S.D. for each group. Statistical
analysis was performed by analysis of variance with a multiple com-
parison test (Bonferroni’s multiple t-test). Di¡erences were considered
to be statistically signi¢cant when the P values were less than 0.05.
3. Results
3.1. E¡ect of BSO on the renal total GSH levels
To determine the e¡ect of BSO on the levels of total GSH
(reduced and oxidized forms) in rat kidneys, we examined the
time course of the changes in the total GSH content after the
BSO injection (Fig. 1). Intraperitoneal administration of BSO
(2 mmol/kg body weight) rapidly decreased the total GSH
levels at 2.5 h after the injection (197.2 þ 25.4 Wg/g wet tissue)
and the levels were further reduced at 5 h (117.7 þ 23.6 Wg/g
wet tissue) as compared to the control levels (779.8 þ 76.8 Wg/g
wet tissue). The levels of total GSH seemed to be increased at
24 h (273.9 þ 27.9 Wg/g wet tissue). These results showed that
administration of BSO abruptly diminished the renal total
GSH levels.
3.2. Induction of HO-1 protein in rat kidneys after IR
To determine the e¡ect of renal IR on the expression of
HO-1, we examined the time course of the levels of HO-1
protein in rat kidneys after the start of reperfusion following
45 min of ischemia (Fig. 2). Although HO-1 protein was not
detected in rat kidneys treated with 45 min of ischemia alone,
the band of HO-1 was ¢rst detected at 4 h and gradually
increased to 24 h after the start of reperfusion. HO-1 protein
was also undetectable in normal rat kidneys (data not shown).
On the other hand, the levels of HO-2 protein were substan-
tially unchanged during experimental periods.
Fig. 1. Renal total GSH levels after BSO injection. BSO (2 mmol/
kg body weight) was intraperitoneally injected into rats. At the indi-
cated times, renal total GSH levels were determined as described in
Section 2. Data represent the mean þ S.D. of ¢ve or six rats per
group. *P6 0.05, normal rats vs. BSO-treated rats.
Fig. 2. Immunoblot analysis of HO-1 and HO-2 proteins in rat kidneys with IR. Rats underwent 45 min of ischemia followed by various times
of reperfusion. At the indicated times after the start of reperfusion, the kidneys were isolated and the tissue extracts (100 Wg/lane) were ana-
lyzed by Western blot analysis using antibodies against rat HO-1 and HO-2, respectively. 0 denotes the 45 min of ischemia alone.
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3.3. E¡ect of BSO on the levels of HO-1 protein in rat kidneys
To determine the changes in the levels of HO-1 protein after
BSO administration, we examined the time course of the levels
of HO-1 protein in rat kidneys after BSO injection (Fig. 3).
Intraperitoneal injection of BSO (2 mmol/kg body weight)
obviously induced the HO-1 protein at 4 h after the injection
and the high levels of HO-1 protein were sustained to 6^24 h.
In addition, we con¢rmed that the expression of HO-1 protein
was induced reproducibly at 5 h after the BSO administration.
On the other hand, the levels of HO-2 protein were substan-
tially una¡ected by BSO administration (data not shown).
3.4. E¡ect of BSO pretreatment on the acute renal injury
BSO (2 mmol/kg body weight) was intraperitoneally admin-
istered into rats at 5 h prior to the renal ischemia, the levels of
BUN and SCr, as markers for renal injury, were assessed at
24 h after the start of reperfusion following 45 min of ische-
mia (Fig. 4). The levels of BUN and SCr in rats treated with
IR (BUN, 135 þ 39.9 mg/dl; SCr, 2.46 þ 0.91 mg/dl) were ele-
vated as compared to the control rats (BUN, 21.5 þ 1.5 mg/dl ;
SCr, 0.63 þ 0.05 mg/dl). When BSO was administered into rats
at 5 h prior to the renal ischemia, the renal injury (BUN,
47.0 þ 19.6 mg/dl; SCr, 0.78 þ 0.30 mg/dl) was obviously im-
proved as compared to the rats treated with IR. On the other
hand, administration of ZnPP, an inhibitor of HO activity,
abolished the e⁄cacy of BSO pretreatment (BUN,
132.6 þ 28.3 mg/dl ; SCr, 2.57 þ 0.80 mg/dl). ZnPP treatment
alone (BUN, 17.6 þ 2.2 mg/dl ; SCr, 0.51 þ 0.05 mg/dl) did not
show any di¡erences as compared to the control rats. These
results showed that BSO pretreatment ameliorated the renal
IR injury. This improvement may be mediated directly or
indirectly by HO-1 induction.
3.5. Histopathological analysis
To con¢rm the above ¢ndings, histopathological analysis
was performed (Fig. 5). Histological data showed that there
were no signi¢cant di¡erences between control, BSO-, and
ZnPP-treated rat kidneys. On the other hand, rat kidneys
treated with IR clearly showed tubular damage, that is, dila-
tion of the renal tubules with proteinaceous casts. These
changes caused by IR were markedly improved with pretreat-
ment of BSO. However, administration of ZnPP prior to the
BSO treatment eliminated the therapeutic e¡ects of BSO for
IR injury.
4. Discussion
Cells primed by mild stress transiently induce stress proteins
and thereby develop tolerance to the next severe stress. In-
duction of HO-1 in response to various oxidative insults has
been shown to be implicated in a cytoprotective mechanism to
prevent cells and tissues from further oxidative injury. In view
of its important functions, there has been great interest in
assessing the potential use of HO-1 as a therapeutic target
for various oxidative injuries [6,15,16]. Therefore, if we can
use non-toxic drugs to induce HO-1 in advance, it seems to be
a clinically useful tool. Furthermore, to clarify the molecular
mechanism of such drugs leads to the development of more
useful medicine. In this study, our ¢ndings showed that the
prior induction of HO-1 with BSO ameliorated the renal is-
chemic injury. BSO concentration used in this experiment did
not a¡ect any toxic in£uence on the normal renal function.
Under this condition, the expression of HO-1 might be in-
duced by changing the redox state without harmful e¡ects.
Although several ¢ndings have been reported, the mecha-
Fig. 3. Immunoblot analysis of HO-1 protein in rat kidneys after BSO administration. BSO (2 mmol/kg body weight) was injected intraperito-
neally into rats. At the indicated times, the kidneys were isolated and the tissue extracts (100 Wg/lane) were analyzed by Western blot analysis
using antibody against rat HO-1. 0 denotes the untreated control rats. Lower gel showed that the kidney samples were isolated from three dif-
ferent rats in each experimental group.
Fig. 4. E¡ect of BSO pretreatment on the subsequent renal IR in-
jury in the rats. BSO (2 mmol/kg body weight) was intraperitoneally
injected into rats at 5 h before the start of ischemia. After 45 min
of ischemia followed by 24 h of reperfusion, BUN and SCr levels
were determined. C, untreated control rats. Experimental details
were described in Section 2. Data represent the mean þ S.D. of ¢ve
or six rats per group. *P6 0.05, control rats vs. rats treated with
IR; **P6 0.05, rats treated with IR vs. BSO-pretreated rats with
IR; ***P6 0.05, BSO-pretreated rats with IR vs. ZnPP- and BSO-
treated rats with IR.
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nisms behind HO-1-mediated cytoprotection are not fully
understood. The end-products of heme degradation, including
biliverdin, bilirubin and CO, show important physiological
roles. Both biliverdin and bilirubin are e⁄cient peroxyl radical
scavengers that possess potent antioxidant properties [17,18].
Because the postischemic damage is at least in part considered
to be related to the generation of free oxygen radicals, both
bilirubin and biliverdin may play a protective role against
reactive oxygen species generated by renal IR. In addition,
CO is a potent activator of soluble guanylate cyclase [19]
and a vasodilator substance [20]. It has been recently reported
that inhaled CO mitigates lung IR injury in mice [21] and CO
also protects against hepatobiliary dysfunction in endotoxin-
treated rat liver [22]. Therefore, the bene¢cial e¡ects of HO-1
preinduction with BSO may be derived from production of
bilirubin and CO. In addition to the HO-1 induction, GSH
depletor may induce a number of acute phase proteins and
antioxidant enzymes.
Tolerance induction in the kidney by BSO is a promising
novel strategy for preventing the critical problems associated
with the IR injury. Further studies that clarify the mechanism
of tolerance induction will provide clinically useful strategies
against tissue injury induced by the oxidative stress.
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Fig. 5. Histopathological analysis of rat kidneys. Control, untreated rat kidneys. Experimental details were described in Section 2. These ¢gures
show the cortex including glomeruli. Hematoxylin and eosin, magni¢cation U40.
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